AGP Executive Report
Last update: 9 hours agoLong COVID: A new study links weaker handgrip strength and faster muscle fatigue with more severe post-COVID symptoms. Researchers say grip testing may offer clues to muscle problems, but it is not a diagnostic test. German Pharma: The US FDA approved pritelivir, developed by Germany’s AiCuris, for persistent herpes lesions in immunocompromised adults who do not respond to standard antivirals. In a trial, lesions healed by day 28 in about 63% of patients taking the drug, versus 34% on comparison treatments. Gene Therapy: Germany has treated its first patient with CRISPR therapy since the treatment’s approval, marking a milestone for access to gene-editing care. Global Health: Germany plans to increase support for African drug and vaccine makers, aiming to strengthen local production. The issue was also in focus at the World Health Summit in Berlin, as coverage warned that the global health system is under growing strain.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
